Tag Archives: IMV

Oppenheimer Sticks to Its Buy Rating for IMV (IMV)

In a report released yesterday, Jay Olson from Oppenheimer maintained a Buy rating on IMV (IMV – Research Report), with a price target of C$9.00. The company’s shares closed last Monday at $2.87. According to TipRanks.com, Olson ‘s ranking currently

Oppenheimer Keeps a Buy Rating on IMV (IMV)

Oppenheimer analyst Jay Olson maintained a Buy rating on IMV (IMV – Research Report) on January 24 and set a price target of C$9.00. The company’s shares closed last Monday at $4.19. According to TipRanks.com, Olson ‘s ranking currently consits

IMV (IMV) Received its Third Buy in a Row

After H.C. Wainwright and Oppenheimer gave IMV (NASDAQ: IMV) a Buy rating last month, the company received another Buy, this time from B.Riley FBR. Analyst Mayank Mamtani reiterated a Buy rating on IMV today and set a price target of

Analysts Offer Insights on Healthcare Companies: IMV (NASDAQ: IMV) and Sangamo Biosciences (NASDAQ: SGMO)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on IMV (IMV – Research Report) and Sangamo Biosciences (SGMO – Research Report) with bullish sentiments. IMV (IMV) H.C. Wainwright analyst Joseph Pantginis

Echelon Wealth Partners Keeps a Buy Rating on IMV (IMV)

In a report issued on November 8, Douglas Loe from Echelon Wealth Partners maintained a Buy rating on IMV (IMV – Research Report), with a price target of C$12.25. The company’s shares closed last Monday at $2.66, close to its

IMV (IMV) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on IMV (IMV – Research Report) today and set a price target of $11.50. The company’s shares closed last Monday at $2.58, close to its 52-week low of $2.25. According to